GLP-1s could be linked to more than 150 deaths

GLP-1 drugs including semaglutide, liraglutide and tirzepatide may be linked to more than 150 deaths and thousands of adverse reactions, according to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), specifically data collected by its Yellow Card biobank. Alongside deaths, the drugs are suspected of having been linked to gastrointestinal symptoms, psychiatric disorders and nervous system disorders.